Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

The systemic process for referring SCLC patients from community clinics to academic centers for trials is too slow. The most effective solution is not a systems overhaul but for community physicians to build direct communication channels (text, email) with academic specialists to "make a spot" and bypass formal referral backlogs.

The industry's standard practice of selecting sites based on pre-existing relationships and convenience—the "easy button"—is a primary driver of failure. This leads to 80% of activated sites missing enrollment targets and 30% enrolling zero patients, a massive, systemic inefficiency that data-driven approaches can solve.

In cell therapy trials costing hundreds of thousands per patient, spending a fraction on services like childcare or travel is a high-leverage investment. It makes participation feasible for more patients, improving enrollment speed and overall trial efficiency.

A primary obstacle preventing community SCLC patients from joining clinical trials is not their unwillingness, but physicians not offering the option due to assumptions about patient interest or eligibility. The first step to improving enrollment is ensuring the conversation happens.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Many clinical trials fail not because the science is wrong, but because of operational issues like patient recruitment and retention. These problems often stem from overly burdensome and rigid trial designs that deter participation, a preventable error.